|
rs4374383
|
|
|
0.710 |
GeneticVariation |
BEFREE |
<i>MERTK</i> rs4374383 A carriers had a lower risk of liver fibrosis progression than G carriers, supporting the hypothesis that this SNP seems to have a critical role in the pathogenesis of liver disease in HCV-infected patients.
|
30477195 |
2018 |
|
rs116399066
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Impact of IFNL4 Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients.
|
31260374 |
2019 |
|
rs11790131
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
A new 3p25 locus is associated with liver fibrosis progression in human immunodeficiency virus/hepatitis C virus-coinfected patients.
|
27339598 |
2016 |
|
rs13401937
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Impact of IFNL4 Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients.
|
31260374 |
2019 |
|
rs143633948
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
A new 3p25 locus is associated with liver fibrosis progression in human immunodeficiency virus/hepatitis C virus-coinfected patients.
|
27339598 |
2016 |
|
rs2492965
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Impact of IFNL4 Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients.
|
31260374 |
2019 |
|
rs2856723
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Human leukocyte antigen variants and risk of hepatocellular carcinoma modified by hepatitis C virus genotypes: A genome-wide association study.
|
28921602 |
2018 |
|
rs2978048
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Genome-wide association study to characterize serum bilirubin elevations in patients with HCV treated with GS-9256, an HCV NS3 serine protease inhibitor.
|
24503447 |
2014 |
|
rs35384524
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Impact of IFNL4 Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients.
|
31260374 |
2019 |
|
rs35467001
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
A new 3p25 locus is associated with liver fibrosis progression in human immunodeficiency virus/hepatitis C virus-coinfected patients.
|
27339598 |
2016 |
|
rs35897606
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
A new 3p25 locus is associated with liver fibrosis progression in human immunodeficiency virus/hepatitis C virus-coinfected patients.
|
27339598 |
2016 |
|
rs4803221
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Impact of IFNL4 Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients.
|
31260374 |
2019 |
|
rs56378326
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Impact of IFNL4 Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients.
|
31260374 |
2019 |
|
rs59888390
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Impact of IFNL4 Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients.
|
31260374 |
2019 |
|
rs62042908
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Impact of IFNL4 Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients.
|
31260374 |
2019 |
|
rs6445096
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Impact of IFNL4 Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients.
|
31260374 |
2019 |
|
rs7262634
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Genome-wide association study to characterize serum bilirubin elevations in patients with HCV treated with GS-9256, an HCV NS3 serine protease inhibitor.
|
24503447 |
2014 |
|
rs72799981
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Impact of IFNL4 Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients.
|
31260374 |
2019 |
|
rs73084982
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
A new 3p25 locus is associated with liver fibrosis progression in human immunodeficiency virus/hepatitis C virus-coinfected patients.
|
27339598 |
2016 |
|
rs73132848
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
A new 3p25 locus is associated with liver fibrosis progression in human immunodeficiency virus/hepatitis C virus-coinfected patients.
|
27339598 |
2016 |
|
rs7332270
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Impact of IFNL4 Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients.
|
31260374 |
2019 |
|
rs74597329
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Impact of IFNL4 Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients.
|
31260374 |
2019 |
|
rs75707332
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Impact of IFNL4 Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients.
|
31260374 |
2019 |
|
rs76755915
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Impact of IFNL4 Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients.
|
31260374 |
2019 |
|
rs76810409
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Impact of IFNL4 Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients.
|
31260374 |
2019 |